FDA Clearance Tracker · P140003-S088
Impella 2.5 System, Impella CP System, Impella CP with SmartAssist System, Impella 5.0 System, Impella LD System,Impella
Last checked: Nov 20, 2026Latest source record: Apr 19, 2022 (this decision)Source: openFDAMethods & limitations
Decided
Apr 19, 2022
Approved
Time to decision
257 days
Received Aug 5, 2021. Calendar days, including time FDA spent waiting on the applicant.
Pathway
PMA supplement
Normal 180 Day Track
Device class
Class III
The decision
- FDA number
- P140003-S088
- Device name
- Impella 2.5 System, Impella CP System, Impella CP with SmartAssist System, Impella 5.0 System, Impella LD System,Impella
- Applicant
- Abiomed, Inc.
- Applicant location
- Danvers, MA
- Received
- Aug 5, 2021
- Decided
- Apr 19, 2022
- Decision
- Approved
- Supplement type
- Normal 180 Day Track
- Reason for supplement
- Change Design/Components/Specifications/Material
- Original approval
- P140003
Device type
- Device class
- Class III
- Specialty
- Cardiology
FDA's approval statement
As written in FDA's record.
Approval for revising the Instructions for Use to allow the use of sodium bicarbonate (25 or 50 mEq/L) as an alternative to heparin (25 or 50 U/mL) in the purge fluid during clinical use of the Impella catheters in patients intolerant to heparin or in whom heparin is contraindicated.
Source documents
Other decisions for Abiomed, Inc.
Matched on the applicant name as FDA recorded it. A company that files under several names will have more.
K252766 · Decided Oct 8, 2025 · 40 days after receipt
Device type: Introducer, Catheter (DYB) · Cardiology
7 more FDA decisions with a free account
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.